OpGen Highlights Strong Performance of Acuitas® Resistome Test at ASM Microbe 2016
June 20 2016 - 11:30AM
OpGen, Inc. (NASDAQ:OPGN), a precision medicine
company using molecular diagnostics and bioinformatics to combat
infectious disease, today presented data that support the use of
its Acuitas® Resistome Test in epidemiological studies to aid in
routine evaluations for mechanisms of resistance among carbapenem
resistant Enterobacteriaceae (CRE) at ASM Microbe 2016 in Boston.
The poster titled “Performance of Two Methods for Detection of
Carbapenem Resistance Mechanism Among Enterobacteriaceae” was
presented by Shelley Miller, Ph.D., D (ABMM), Clinical Instructor,
Clinical Microbiology, Development Section at University of
California, Los Angeles. Key findings include:
- The Acuitas Resistome Test performed comparably to RT-PCR for
the detection of carbapenemase genes.
- This test provides additional genetic data on resistance
mechanisms, helping to provide CRE positive results contrasted with
negative results from the lab-developed RT-PCR.
“The need for rapid infection control is greater today given the
rapid rate of resistance that we are seeing to what were once
curative medicines,” said Romney Humphries, Ph.D., Assistant
Professor of Pathology and Laboratory Medicine at University of
California, Los Angeles. “It is imperative that health systems take
measures to routinely evaluate for mechanisms of resistance among
carbapenem resistant Enterobacteriaceae.”
The Acuitas Resistome Test detects antibiotic resistance genes
associated with organisms such as: Klebsiella pneumoniae,
Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa,
Enterobacter cloacae, and Citrobacter freundii. Results are then
delivered from OpGen Clinical Services Laboratory within 24 hours
of receipt of specimens.
“These data further validate the Acuitas Resistome Test as
efficacious for the detection of carbapenemase genes,” stated
Kevin Krenitsky, M.D., President of OpGen. “It is critical that
hospitals and health systems have access to precision medicine
tools to rapidly combat evolving MDROs.”
ASM (American Society for Microbiology) Microbe 2016 integrates
ASM’s two premier events, its General Meeting and ICAAC
(Interscience Conference on Antimicrobial Agents and Chemotherapy).
This conference is the largest gathering of microbiologists in the
world and showcases the best microbial sciences while providing a
unique forum to explore the full spectrum of microbiology from
basic science to full translation and application.
About OpGenOpGen, Inc. is developing and
deploying precision medicine tools to combat infectious disease in
global healthcare settings, helping physicians improve patient
outcomes by providing more rapid information about life-threatening
infections and decreasing the spread of infections caused by
multidrug-resistant microorganisms. OpGen offers a full portfolio
of in vitro diagnostic products and clinical laboratory services
that employ state-of-the-art molecular diagnostics and
bioinformatics. Its QuickFISH® products are a suite of FDA-cleared
and CE-marked diagnostics used to rapidly detect pathogens in
positive blood cultures. Clinical laboratory services utilize
the Acuitas® products, including the MDRO Gene Test, the Resistome
Test, microbial Whole Genome Sequence Analysis and Acuitas
Lighthouse™ bioinformatics system designed to detect, type, track
and trend antibiotic resistant organisms in real-time. Learn more
at www.opgen.com and follow OpGen on Twitter and
LinkedIn.
OpGen Forward-Looking Statements This
press release includes statements relating to the company's Acuitas
MDRO, products and clinical laboratory services. These statements
and other statements regarding our future plans and goals
constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and are intended to qualify for
the safe harbor from liability established by the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to risks and uncertainties that are often difficult to
predict, are beyond our control, and which may cause results to
differ materially from expectations. Factors that could cause our
results to differ materially from those described include, but are
not limited to, the rate of adoption of our products and services
by hospitals and other health care providers, the success of our
commercialization efforts, the effect on our business of existing
and new regulatory requirements, and other economic and competitive
factors. For a discussion of the most significant risks and
uncertainties associated with OpGen's business, please review our
filings with the Securities and Exchange Commission (SEC). You are
cautioned not to place undue reliance on these forward-looking
statements, which are based on our expectations as of the date of
this press release and speak only as of the date of this press
release. We undertake no obligation to publicly update or revise
any forward-looking statement, whether as a result of new
information, future events or otherwise.
Contacts:
OpGenMichael FarmerDirector, Marketing(240)
813-1284mfarmer@opgen.comInvestorRelations@opgen.com
Investor RelationsLHAKim Sutton Golodetz(212)
838-3777kgolodetz@lhai.comorBruce Voss(310)
691-7100bvoss@lhai.com
OpGen MediaMacDougall Biomedical
CommunicationsCammy Duong781-235-3060cduong@macbiocom.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2024 to Aug 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Aug 2023 to Aug 2024